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Abstract: Mephedrone is a β-ketoamphetamine belonging to the family of synthetic cathinones, an 
emerging class of designer drugs known for their hallucinogenic and psychostimulant properties as 
well as for their abuse potential. The aim of this review was to examine the emerging scientific 
literature on the possible mephedrone-induced neurotoxicity, yet not well defined due to the limited 
number of experimental studies, mainly carried on animal models. Relevant scientific articles were 
identified from international literature databases (Medline, Scopus, etc.) using the keywords: 
“Mephedrone”, “4-MMC,” “neurotoxicity,” “neuropharmacology”, “patents”, “monoamine 
transporters” and “neurochemical effects”. Of the 498 sources initially found, only 36 papers were 
suitable for the review. Neurotoxic effect of mephedrone on 5-HT and DA systems remains 
controversial. Although some studies in animal models reported no damage to DA nerve endings in 
the striatum and no significant changes in brain monoamine levels, some others suggested a rapid 
reduction in 5-HT and DA transporter function. Persistent serotonergic deficits were observed after 
binge like treatment in a warm environment and in both serotonergic and dopaminergic nerve 
endings at high ambient temperature. Oxidative stress cytotoxicity and an increase in frontal cortex 
lipid peroxidation were also reported. In vitro cytotoxic properties were also observed, suggesting 
that mephedrone may act as a reductant agent and can also determine changes in mitochondrial 
respiration. However, due to the differences in the design of the experiments, including temperature 
and animal model used, the results are difficult to compare. Further studies on toxicology and 
pharmacology of mephedrone are therefore necessary to establish an appropriate treatment for 
substance abuse and eventual consequences for public health. 
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1. INTRODUCTION 
 Mephedrone is a β-ketoamphetamine [4-methylmeth- 
cathinone; 4-methylephedrone; 4-MMC; IUPAC: 2-(methyl- 
amino) -1-(4-methylphenyl)propan-1-one] belonging to the 
family of synthetic cathinones [1], an emerging class of 
designer drugs known for their hallucinogenic and psycho- 
stimulant properties, some of which they share with 3,4 
methylenedioxymethamphetamine (MDMA), methamphetamine, 
amphetamine and cocaine [2]. Due to those effects, mephedrone 
is becoming increasingly popular as a recreational drug of 
abuse, not only among youngsters, but also in other age 
groups, including but not limited to young and older adults 
[3-5]. Mephedrone was first synthesized in 1929 as a ring-
substituted cathinone (4-methyl aromatic analogue of 
methcathinone) and its structure, such that of other synthetic  
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cathinones (e.g. methylone or methylenedioxypyrovalerone- 
MDPV) is somehow related to that of the phenethylamine 
family [6] (Fig. 1). Mephedrone is available from several 
selling sources, such as internet suppliers, head shops [7], 
street drug dealers, as a “legal high” or “bath salt” under 
different street names including “4-MMC”, “meow meow”, 
“M-Cat”, “MMCAT”, “bubbles” and “Crab”. 
 It can be obtained in fine crystals or as white or yellowish 
powder and less frequently in tablet or capsule form [8-11]. 
The remarkable increase of its use in recent years has made it 
a significant public health threat both in the US and in 
Europe [9, 12, 13]. 
 Mephedrone and structurally related compounds were 
categorized as Class B compounds in the UK in April  
2010 under the Misuse of the Drugs Act Legislation [14]. 
Furthermore, in October 2011, the US Drug Enforcement 
Administration (DEA) issued a temporarily Schedule I for 
the more frequently encountered substances of the 
cathinones class, including mephedrone among others, in 
response to this increasing epidemic of its abuse [15]. In 
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many other European and non-European countries, this drug 
has also been banned to limit its availability. 
 Many adverse effects have been reported following the 
use of “Bath salts” and especially β-ketoamphetamine 
including sleeplessness, psychosis, anxiety, depression and 
cardiovascular complications [9, 16, 17]. β-ketoamphetamines 
are known to block serotonin transporter (SERT) [18-24] and 
determine the release of monoamines in vivo [25-28] and  
in vitro [20, 25, 29, 30]. Specifically, vasoconstriction and 
bruxism observed in acute intoxication with mephedrone [1] 
and case of a 22-year-old male who displayed diaphoresis, 
clonus, hypertonia, hyper-reflexia and was tachycardic after 
mephedrone ingestion supported the idea that substance 
toxicity may be linked to the serotonin syndrome [31]. 
 Not only severe intoxications have been attributed to 
mephedrone consumption, but also a number of fatal cases 
where the drug either alone or in combination to other 
substances, such as: MDMA, GHB and heroin was identified 
in biological matrices from deceased [32, 33]. 
 Notwithstanding these evidences on mephedrone hazard, 
limited and controversial information is currently available 
on the way mephedrone acts on the central nervous system 
(CNS) and on its neurotoxicity potential. 
 Mephedrone shares a number of effects with MDMA and 
methamphetamine on the CNS, interacting with monoamine 
plasma membrane transporters for serotonin (5-hydro- 
xytryptamine, 5-HT) dopamine (DA) and likely 
norepinephrine (NE) [19, 23, 34-39], blocking their reuptake 
[19, 34, 35, 37, 39] while stimulating their release [26, 34, 
38, 40, 41]. It was originally hypothesized that mephedrone 
could cause methamphetamine-like neurotoxicity due to the 
fact that it simultaneously stimulates both DA release and 
inhibition of its uptake, cause hyperthermia and increase the 
locomotor activity [42-45]. Moreover, mechanistic and 
structural similarities with MDMA and methamphetamine 
led to the hypothesis that mephedrone could also cause toxic 
effects to DA nerve terminals. However, this hypothesis was 
ruled out after a number of studies [12, 38, 40, 46-48]. In 
addition, its effects are evident not only on dopaminergic and 
-serotoninergic systems, but also on other pathways. As an 
example, German et al. [41] demonstrated that neuropeptide 
neurotensin content in the limbic system and basal ganglia 
was increased after four injections of mephedroneat the dose 
of 25 mg/kg. 
 To clarify all the above-reported issues, this review 
examined the emerging scientific literature on the possible 
mephedrone-induced neurotoxicity and the neuro- 
pharmacological profile of this substance yet not well 
defined due to the limited number of experimental studies 
mainly carried out in animal models [26, 34, 37, 49, 50]. 
2. MATERIALS AND METHODS 
 Relevant scientific articles were searched from Medline, 
Cochrane Central, Scopus, Web of Science, Science Direct, 
EMBASE and Google Scholar, up to March 2016 using the 
following keywords: “Mephedrone”, “4-MMC,” “neurotoxicity,” 
“neuropharmacology”, “patents”, “monoamine transporters” 
and “neurochemical effects”. The main keyword “Mephedrone” 
was individually searched and then again in association to 
each of the others. The 498 articles initially found were 
screened to exclude duplicate sources and papers not suitable 
for the purpose of the review. Only 36 papers (26 experimental 
studies, 6 review articles, 3 patents and 1 case report) were 
included in the present review [9, 12, 19, 23, 26, 34, 35, 37-
40, 49-73]. All sources have been screened independently by 
three of the authors, and selected by at least two of them. 
3. RESULTS 
 Selected experimental studies in rodent animal models 
(mouse and rat) investigating the effects of mephedrone on 
DA and 5-HT transporters, DA and 5-HT depletion, tyrosine 
hydroxylase and tryptophan hydroxylase expression, 
cytotoxic damage and oxidative stress and microglial and 
astrocytic activation, are summarized in Table 1. 
3.1. Dopamine and Serotonin Transporters 
 A number of studies reported that mephedrone acts as an 
uptake inhibitor of monoamine neurotransmitters in the 
CNS, suggesting this drug could be a transporter blocker [19, 
34, 35, 37, 39, 51]. Hadlock et al. [34] studied the effects of 
mephedrone in a study on male rats. Rodents were 
administered 4 x 10 or 25 mg/kg subcutaneously every two 
 
Fig. (1). Structures of cathinone, mephedrone, methylone, 
methylenedioxypyrovalerone (MDPV), amphetamine, methamphetamine 
and methylenedioxymethamphetamine (MDMA). 
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Table 1. Experimental studies reporting the effects of mephedrone on dopamine, serotonin, monoamine transporters activity, microglia/astrocytic (GFAP) activation, 
oxidative stress cytotoxicity, etc. 
Ref. Animal 
Experiment 
Conditions 
Route of 
Administration 
Posology DA 5-HT 
DAT 
Activity 
SERT Activity 
NET 
Activity 
TH – 
TPH 
Microglia/ 
Astrocytic 
(GFAP) 
Activation 
Oxidative 
Stress 
Ctotoxicity 
DA-D2  
5-HT 
Receptors 
Damage 
Hadlock 
et al. 
[34] 
Male Rats 
warm 
environment ≥ 
27°C 
s.c. 
In vitro 
experiment. 
Rats 
self-
administration. 
4 X 10 or 25 
mg/kg x 
injection, every 
two hours such 
as to mimic 
binge-like 
intake 
no effects 
reduction 
assessed 7 days 
after exposure 
Rapid 
decrease in 
function 
(within an 
hour) in 
striatum 
Rapid decrease in 
function (within 
an hour) in 
hippocampus 7 
days after 
exposure 
     
Persistent 
serotonergic 
deficits ↓ SERT 
activity 5-HT 
levels ↓ 
  In Vitro   
Release in  
in vitro 
experiment 
(striatal 
suspension)  
> than MDMA 
similar to METH 
   
 
     
Baumann 
et al. 
[38] 
Male Rats 
Repeated 
administrations 
(22±2 °C) 
s.c. 
3 x 3 or 10 
mg/kg 1 every 2 
hours 
         
NO long-term 
change in 
striatal or 
cortical amines 
2 weeks after 
intake 
  In Vivo 
microdialysis 
i.v. 
0.3 and 1.0 
mg/kg 
+ dose related 
release (nucleus 
accumbens) 
++ dose related 
release (nucleus 
accumbens) 
        
  In Vitro     
4-MMC is a 
non-selective 
substrate: 
RELEASE 
from DAT 
4-MMC is a non-
selective 
substrate: 
RELEASE from 
SERT 
4-MMC is 
a non- 
selective 
substrate: 
RELEASE 
from NET 
     
Kehr et 
al. [26] 
Rats  s.c. 1-3 mg/kg-1 
Release in 
nucleus 
accumbens 
(values similar 
to AMPH but 
more potent than 
MDMA ) 
Release in 
nucleus 
accumbens 
(values similar 
to MDMA, 
more potent 
than AMPH) 
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(Table 1) contd…. 
Ref. Animal 
Experiment 
Conditions 
Route of 
Administration 
Posology DA 5-HT DAT Activity 
SERT 
Activity 
NET 
Activity 
TH – TPH 
Microglia/ 
Astrocytic 
(GFAP) 
Activation 
Oxidative 
Stress 
Ctotoxicity 
DA-D2  
5-HT 
Receptors 
Damage 
Angoa-
Pérez et 
al. [12] 
Female 
Mice 
 i.p. 
4X 20 or 40 
mg/kg every two 
hours 
No permanent 
decrease after 
binge like 
scheme 
exposure 
 
No permanent 
activity 
decrease after 
binge like 
scheme 
exposure 
  
No permanent 
decrease of 
TH after binge 
like scheme 
exposure 
No 
microglial 
or 
astrocytic 
activation 
(GFAP) 
  
examination after 
two or seven 
days, following 
administration, 
showed no 
neurotoxicity 
involving DA 
nerve terminals in 
the striatum NO 
permanent 
reduction in TH, 
DA, DAT 
activity 
Angoa-
Pérez et 
al. [56] 
Female 
Mice 
 i.p. 
4-MMC (10, 20 
or 40 mg/kg)  
30 minutes before 
injecting METH 
4 x 2.5 or 
5.0mg/kg, or 
AMPH 
4x 5.0 mg/kg, or 
MDMA 
4 x 20 mg/kg, 
every two hours). 
Co-
administration 
enhanced DA 
levels reduction 
 
Co-
administration 
enhanced 
DAT protein 
levels 
reduction 
  
Co-
administration 
enhanced TH 
levels 
reduction 
   
NO protective 
effects of 
4-MMC (as a 
DAT inhibitor) 
on METH, 
MDMA or 
AMPH co-
administration 
but 
ENHANCED 
NEUROTOXICI
TY on DA nerve 
terminals 
Angoa-
Pérez et 
al. [40] 
Female 
Mice 
 i.p. 
4-MMC (4x 20 
mg/kg every 2 
hours) alone or 30 
minutes before 
injecting METH 4 
x 5.0mg/kg, or 
MDMA 4 x 20 
mg/kg. 
 
No persistent 
decrease if 
administered 
alone. No 
enhanced 
decrease in co-
administration 
 
No persistent 
decrease if 
administered 
alone. No 
enhanced 
decrease in 
co-
administration 
 
No persistent 
decrease in 
TPH2 if 
administered 
alone. No 
enhanced 
decrease in 
co-
administration 
NO 
microglia or 
astrocytic 
activation 
(GFAP) 
  
NO TOXICITY 
on 5HT nerve 
endings 
HIPPOCAMPUS 
the authors 
underline that 
mice are less 
susceptible to 
MDMA 5-HT 
damage than Rats 
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(Table 1) contd…. 
Ref. Animal 
Experiment 
Conditions 
Route of 
Administration 
Posology DA 5-HT 
DAT  
Activity 
SERT 
Activity 
NET 
Activity 
TH – TPH 
Microglia/ 
Astrocytic (GFAP) 
Activation 
Oxidative 
Stress 
Ctotoxicity 
DA-D2  
5-HT 
Receptors 
Damage 
López-
Arnau et 
al. [55] 
Adolescent 
Rats 
High ambient 
temperature 
(26±2 °C) 
s.c. 
3 × 
25mg/kg, in 
a day, with a 
2 h interval 
between 
doses, for 2 
days 
  
30% density 
reduction in 
the frontal 
cortex 
40% density 
reduction in 
frontal cortex 
and 
hippocampus, 
48% density 
reduction in 
striatum 
 
TH and 
TPH2 
expression 
decrease 
NO microgliosis 
significant 
increase in 
lipid 
peroxidation in 
the frontal 
cortex and 
increase of 
glutathione 
peroxidase 
levels 
down 
regulation DA 
D2 receptors 
in striatum 
transporter 
binding and 
enzyme 
markers 
decrease, 
oxidative 
stress: injury at 
the nerve 
terminals. 
Damage in the 
reference 
memory. 
Den 
Hollander 
et al. [60] 
2014 
Male mice 
Male mice 
brain tissue 
and 
SH-SY5Y 
neuroblastoma 
cells in vitro 
study 
 (2µ–2mM) 
for 48 hours 
       
Cytotoxic 
properties in 
vitro (increase 
in LDH release 
due to 
4-MMC above 
500 µM) 
 
LDH increase 
indicating in 
vitro cytotoxic 
damage; 
decrease in 
mitochondrial 
respiration; 
reductant agent 
(redox electron 
donor activity) 
pH increase 
correlated. 
Den 
Hollander 
et al. [48] 
Male mice 
and Rats 
temperature, 
20–23 °C; 
i.p. 
2x30 mg/kg 
daily for 4 
consecutive 
days 
no 
decrease 
after 15 
days 
no decrease 
after 15 days 
       
No changes in 
neurotransmitt
ers (DA and 5-
HT) levels 
after 15 days 
from exposure 
but behavioral 
effects were 
observed and 
working 
memory was 
affected 
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(Table 1) contd…. 
Ref. Animal 
Experiment 
Conditions 
Route of 
Administration 
Posology DA 5-HT 
DAT  
Activity 
SERT 
Activity 
NET 
Activity 
TH – 
TPH 
Microglia/ 
Astrocytic 
(GFAP) 
Activation 
Oxidative 
Stress 
Ctotoxicity 
DA-D2  
5-HT 
Receptors 
Damage 
Martinez-
Clemente 
et al. [58] 
Mice and 
in vitro 
experiment 
cerebral 
cortex 
neurons 
culture 
Schedule 1 
temperature 
(26±2 °C) 
s.c. 
4 x 50 mg/kg 
2 h intervals 
  
loss in DA 
reuptake  
sites of 50% 
significant 
loss in the  
hippocampus 
   
Persistent (7 days after  
exposure) neurotoxicity 
on  
5-HT and 
dopaminergic systems 
  
Schedule 2 
temperature 
(26±2 °C) 
s.c. 
4 x 25 mg/kg 
2 h intervals 
  transient  
decrease 
no loss    Transient dopaminergic 
injury 
  
Schedule 3 
temperature 
(26±2 °C) 
s.c. 
3 x 25 mg/kg  
2 h intervals  
for two days  
consecutively 
  
DA  
transporter 
loss 
5-HT  
transporter  
loss 
 
TH and 
TPH  
expression  
decrease 
  
  
  
no cortical or 
striatal 
astrocytic 
activation 
hippocampus: 
apparent 
increase 
in GFAP 
no microglial 
activation 
  
  
  
  
in vitro 
experiment 
concentration  
related  
cytotoxic  
effect > 
MDMA 
D2 density 
decrease in  
striatum  
5-HT 2a  
frontal 
cortex 
Damage in 
dopaminergic nerve  
endings (frontal cortex)  
and serotonergic  
(hippocampus) 
Pifl et al. 
[59] 
Human 
cell lines 
synaptic 
vesicles 
from 
human 
striatum 
   
Release 
from 
monoamine 
transporter 
DAT 
reverse 
transport 
Release 
from 
monoamine 
transporter 
SERT 
reverse 
transport 
-DA-DAT 
uptake 
inhibition 
more potent 
than MDMA -
inhibition of 
vesicular 
uptake 10 fold 
less powerful 
than MDMA 
SERT-
serotonin 
uptake 
inhibition less 
potent than 
MDMA 
NET-Nor- 
adrenaline 
uptake 
inhibition 
= to 
MDMA 
and 
release 
from NET 
reverse 
transport 
    
The less potent(10 
folds) effect of 4-MMC 
on vesicular DA uptake 
in comparison with 
MDMA, could suggest 
an explanation of the 
lower long term effects 
observed with 4-MMC 
compared to MDMA. 
Motbey et 
al. [67] 
Male 
adolescent 
rats 
(21-22±1 
°C) 
i.v. 
self-
administration 
four doses 
were tested 
0.03-0.1-0.3-
1.0 mg/kg 
 
reduction 
in 
metabolite 
5-HIAA 
levels in 
striatum 3 
days after 
treatment 
No density 
changes at the 
43th day from 
the beginning 
of self 
administration 
No density 
changes at the 
43th day from 
the beginning 
of self 
administration 
     
MMC, but not METH, 
self-administration 
decreased striatal 5-
hydroxyindolacetic 
acid (5-HIAA) 
concentrations in 
striatum. 
DA = Dopamine 5-HT = Serotonin DAT = Dopamine Transporter SERT = Serotonin Transporter NET = Norepinephrine transporter METH = Methamphetamine 4-MMC = Mephedrone MDMA = 3,4-methylenedioxy-methamphetamine 
AMPH = Amphetamine LDH = Lactate dehydrogenase TH =Tyrosine Hydroxylase TPH = Tryptophan Hydroxylase 5HIAA = 5-Hydroxyindoleacetic acid GFAP = Glial Fibrillary Acidic Protein s.c. = Subcutaneous injection i.v. = 
Intravenous i.p. = Intra-peritoneal injection. 
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hours. The experiment was carried out in a warm ambient 
temperature at ≥ 27°C. As in case of methamphetamines, 
methcathinone and MDMA, a rapid decrement (within an 
hour) in dopamine transporter (DAT) and serotonin transporter 
(SERT) function was observed in striatum and hippocampus. 
No damages in the dopaminergic system were noticed while 
a persistent serotonergic deficit (5-HT depletion and 
reduction in SERT activity) was observed seven days after 
exposure. This occurrence was also evidenced with MDMA, 
but not with methamphetamine. The authors concluded that 
mephedrone displayed both neurotoxicity and abuse 
potential, and its toxicity, predominantly exerted on 5-HT 
terminals, mimicked that of MDMA with which it shares the 
same subjective sensations on abusers, although mephedrone 
is more potent on DA release in in vitro experiments. On the 
contrary, in another study [38] performed at controlled 
temperature (22±2 °C), no permanent change on striatal or 
cortical amines was observed, when rats underwent repeated 
mephedrone subcutaneous (s.c.) injections (3 x 3 or 10 mg/kg 
every 2 hours). Although data suggest that mephedrone 
blocks the uptake of [3H] DA, [3H] 5-HT and [3H] NE into 
rat brains synaptosomes [52], traditional uptake-inhibition 
assays cannot distinguish between drugs acting as transporter 
substrates and those operating as blockers, taking into 
account that both types prevent the accumulation of  
[3H] neurotransmitters in tissue. Consequently, in vitro 
release assays have been developed to discriminate between 
these two types [23, 53, 54]. It has been shown, that 
mephedrone acts (in vitro) as a non-selective substrate  
on monoamine transporters, thus stimulating the release  
of [3H] 5-HT via SERT and release of [3H]1-methyl-4-
phenylpyridinium ([3H]MPP+) via DAT and NE transporter 
(NET) [23, 38]. According to other authors [55], 
mephedrone, s.c. administered at high ambient temperature 
(26±2 °C) (3 × 25mg/kg) in a day, with two-hours intervals 
between doses, for two days) reduces the density of DAT  
of Table 1: Experimental studies reporting the effects of 
mephedrone on dopamine, serotonin, monoamine trans- 
porters activity, microglia/astrocytic (GFAP) activation, 
oxidative stress cytotoxicity, etc. about 30% in the frontal 
cortex and of 48 and 40%SERT in the striatum and in the 
frontal cortex and hippocampus, respectively. 
 Because of its similarity to methamphetamine and 
methcathinone, known to determine damages to striatum DA 
nerve endings, mephedrone harm potential has been 
investigated in an animal study involving female mice 
treated with a binge like scheme of the substance [12]. This 
regimen consisted in four intra-peritoneal (i.p.) injections (20 or 
40 mg/kg) every two hours since it was proved that injection 
of cathinone derivatives and substituted amphetamines 
determines widespread injury to DA nerve terminals. Although 
locomotor excitement and hyperthermia were observed, two 
or seven days after administration, striatum examination 
showed no neurotoxicity involving DA nerve terminals, as 
no persistent decrease in DAT activity was observed. This 
suggested that mephedrone mechanism of action consists in 
raising DA synaptic amount without causing neurotoxicity. 
Since mephedrone blocks DAT, Angoa-Pérez et al. [56] 
suggested that this drug could protect from the toxicity 
induced by methamphetamines in the same way nomifensine 
(a DAT inhibitor) does. 
 For this purpose, the authors treated mice with mephedrone 
30 minutes before the administration of neurotoxic doses of 
methamphetamines, amphetamines or MDMA. Toxicity was 
observed, ranging from moderate to severe, and essentially 
increased with the co-administration of mephedrone and 
each of the other substances. Although mephedrone had 
previously been described as a substance with poor toxic 
effects on DA nerve terminals, in this study the drug was 
characterized by unsafe interaction with methamphetamines, 
amphetamines and MDMA, commonly co-abused with this 
synthetic cathinone [9, 57]. Mephedrone did not seem to 
damage DA nerve terminals although it increased the 
neurotoxicity of other amphetamine like substances. No 
increase of typical hyperthermia was observed, therefore the 
raise of neurotoxic effects should be considered independent 
from the added raising of body temperature of amphetamines. 
In the author opinion, its neurotoxicity enhancement could 
be indicative of an atypical interaction with DAT. 
 However drug effects on 5-HT nerve endings are 
controversial and not fully established as some authors report 
damage and others do not. In this concern, Angoa-Pérez  
et al. [40] studied the effect of mephedrone alone or in 
combination with MDMA and methamphetamine on 5-HT 
nerve terminals of mice hippocampus. They concluded that 
when mephedrone was administered alone, it caused a non-
persistent decrease in 5-HT, SERT, whereas when it was 
administered together with MDMA or methamphetamine 
there were no changes on the status of 5-HT nerve endings 
other than the effects produced by MDMA and 
methamphetamine alone. It was found that the administration 
of methamphetamine 30 minutes after that of mephedrone 
caused a significant decrease in 5-HT metabolite 5-
hydroxyindoleacetic acid (5HIAA) concentration when 
compared to controls and this effect was not observed when 
mephedrone was administered together with MDMA. 
However, a limitation of this study could have been that the 
authors used mice in their experiments and these animals are 
not so susceptible to the 5-HT damaging of MDMA as rats. 
 To observe the neurotoxic effects of different doses of 
mephedrone in relation with the exposure time, an animal 
study involving mice was designed as detailed [58]. Three 
s.c. drug administration protocols were involved: -1) 50 
mg/kg (four doses); -2) 25 mg/kg (four doses); -3) 25 mg/kg, 
(three doses for two days successively, so as to mimic 
“week-end intake”). Loss in weight gain, hyperthermia, as 
well as aggressive behavior, were observed with all three 
dosages. The first administration program caused seven days 
lasting neurotoxicity on both serotoninergic and dopaminergic 
systems. The second administration program resulted in 
temporary damage on the dopaminergic system, whereas the 
third one, seven days after exposure, in DAT loss (in 
striatum and frontal cortex) and SERT (in the hippocampus) 
loss. After the third administration program, there was a 
predominant damage in the frontal cortex nerve terminals 
(dopaminergic) and hippocampus (serotoninergic). It was 
observed that mephedrone caused a decrease of D2 receptor  
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concentration in the striatum and of 5-HT2 a receptors in the 
frontal cortex; moreover, there was also a depression-like 
behavior and this result suggested a greater vulnerability to 
addictive drugs. All three administration programs caused in 
some mice the onset of a stereotypy: “repeated self-licking 
of the ventral base of the neck” followed by aggressive 
behavior and self-injury. 
 Pifl et al. [59] carried out experiments to compare the 
effects of mephedrone and MDMA on the human NET, DAT 
and SERT monoamine transporters using human cell lines. 
Both drugs showed similar uptake inhibition potency at the 
NET, while mephedrone was more potent at the DAT and 
less potent at SERT compared to MDMA. It was also shown 
that mephedrone-induced release of [3H]MPP+ from NET, 
DAT or SERT expressing cells was exclusively caused by 
carrier-mediated reverse transport through the plasmalemmal 
transporters. Moreover, mephedrone and MDMA had a 
different interaction with the human brain vesicular 
monoamine uptake; with mephedrone displaying a 10 times 
lower transport inhibitory potency compared to MDMA. 
3.2. Dopamine and Serotonin Depletion, Tyrosine 
Hydroxylase and Tryptophan Hydroxylase Expression 
 In vitro experiments on striatal suspension of rats, 
showed that mephedrone [34] was able to determine a DA 
release, similar to that of methamphetamine, displaying more 
adverse effects than those of MDMA. Moreover, rodents 
which self-administered mephedrone, showed a trend 
towards an increase of the intake, therefore suggesting a 
certain abuse liability. In vivo microdialysis studies showed 
that intravenous injection of mephedrone (0.3 or 1.0 mg/kg) 
increased extracellular levels of 5-HT and DA in rat nucleus 
accumbens, and the elevation of monoamines was dose 
related [38]. Some other studies reported a rise of dialysate 
5-HT and DA in rat nucleus accumbens after s.c. 
mephedrone injection (3 mg/kg-1). The rise in 5-HT was 
similar to that following MDMA intake, but higher than that 
caused by amphetamine, whereas DA elevation was 
comparable after mephedrone and amphetamine injection 
and more marked than after MDMA administration [26, 51]. 
It is interesting to note that the elevation in extracellular 5-
HT was of greater significance in comparison to DA increase 
after mephedrone or methylone (another abused synthetic 
cathinone) treatment, suggesting therefore that neuro- 
chemical effects of the latter substances relate more to those 
of MDMA and less to those of methamphetamine [26, 38]. 
However, after repeated s.c. injections of mephedrone or 
methylone (3 x 3 or 10 mg/kg every 2 hours) Baumann et al. 
[38] did not observe any long term alteration in striatal or 
cortical amines. In the study of Lopez-Arnau et al. [55] a 
decrease in biochemical marker of neuronal integrity 
tyrosine hydroxylase (TH) and tryptophan hydroxylase 
(TPH) (catalysts of DA and 5-HT synthesis respectively) 
expressions were observed after mephedrone administration 
along with a down regulation of D2 DA receptors in the 
striatum suggesting damage of the nerve endings. Conversely, 
Angoa-Pérez et al. [12] showed no decrease of DA, TH and 
DAT concentration in murine striatum. In another study, the 
same authors [40] evaluated tryptophan hydroxylase 2 
(TPH2) levels after i.p. administering mephedrone (4x 20 
mg/kg every 2 hours) in mice and did not find any decrease 
in the catalyst expression. In contrast, [58] a decrease of the 
expression of TPH 2 and TH was demonstrated after 
administering a “week-end like” regimen of mephedrone at 
warm temperature to mice (26±2 °C). 
3.3. Cytotoxic Damage and Oxidative Stress 
 Den Hollander et al. [60] assessed cytotoxicity of β-
ketoamphetamines in neuroblastoma SH-SY5S cells, 
evaluating the redox potential and investigating the effect of 
mephedrone in forming protein adducts. It has been shown 
that β-ketoamphetamines increase lactate dehydrogenase 
(LDH) release, which is associated with cytotoxicity in SH-
SY5S neuroblastoma cells. It was also proved that these 
substances are selective and effective reductants of electron 
acceptors, even at physiological pH. However, at pH from 
7.6 to 8.0, the reactivity was six times higher. No formation 
of protein adducts was observed and the authors suggested 
that the reactivity was linked to direct electron transfer by β-
ketoamphetamines. Both mephedrone and methamphetamine 
caused a decrease in mitochondrial respiration, but displayed 
different effects on the electron transport chain. It was 
concluded that this synthetic cathinone was actually able to 
determine cytotoxicity in vitro. 
 Lòpez-Arnau et al. investigated enzymatic and neurological 
changes occurring in adolescent rats after the administration 
of mephedrone mimicking human recreational abuse [55]. 
Changes in memory and spatial learning were also 
investigated. Glutathione peroxidase values were found to be 
elevated in the frontal cortex, striatum and hippocampus and 
a rise in lipid peroxidation was observed in the frontal 
cortex. These findings suggested an mephedrone-related 
oxidative stress. Damage of the reference memory was 
displayed seven days after the end of drug administration, 
whereas spatial learning was not affected. Other authors [58] 
performed in vitro experiments on cerebral cortex neuronal 
cultures, observing a dose-dependent cytotoxic effect of 
mephedrone on these cells, superior to that of MDMA. 
3.4. Microglial and Astrocytic Activation 
 After the administration of mephedrone mimicking 
human recreational abuse, Lopéz-Arnau et al. did not 
observe any microglial activation [55]. These results are in 
agreement with those of Angoa-Pérez et al. [12], who did not 
detect microglial activation or a raise in the levels of glial 
fibrillary acidic protein (GFAP), a measure of astrocytic 
activation, after a binge like scheme of i.p. injections of the 
drug. Another study [40], measuring the GFAP levels on 
mice did not reveal cellular activation in the hippocampus, 
microglia or astrocytes. Martinez-Clemente et al. [58] 
showed that mephedrone did not change GFAP values, nor 
was microglial activation observed. Only in the hippocampus 
an apparent increase in GFAP was noted. 
3.5. Behavioral Effects and Abuse Potential 
 Conditioned place preference and motor activity tests 
were carried out on rats to investigate behavioral effects of 
mephedrone. An increased ambulatory activity after acute 
drug i.p. injection (3, 5, 10, 30 mg/kg) was observed. The 
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pretreatment with DA D1 receptor antagonist SCH 23390 at 
the dose of 0.5, 1, 2 mg/kg, ip inhibited mephedrone -nduced 
ambulation, while pretreatment with D2 DA receptor 
antagonist sulpiride at the dose of 2 mg/kg, i.p. enhanced the 
latter activity. The injection of low doses of the synthetic 
cathinone (0.5 mg/kg, i.p.) for 5 days followed by 10 days of 
abstinence resulted in a sensitization of ambulatory activity 
when mephedrone was re-injected at the same concentration. 
Mephedrone-treated (30 mg/kg, i.p.) rats and mice both 
displayed a preference shift in the cell penetrating peptide 
assay. These findings suggest an abuse liability of the drug 
[50]. 
 Behavioral effects on memory, depression and anxiety 
were investigated two weeks after the administration of 
binge-like dose mephedrone or methylone to mice [48]. DA, 
5-HT, their metabolites and NE levels were also measured 
together with SERT and DAT levels. It was found that 
mephedrone decreased working memory proficiency (T-
maze task), but neurotransmitter concentrations were not 
affected, apart from a 22% reduction in homovanillic acid 
(HVA, a DA metabolite) concentration in murine striatum. 
Depression and anxiety-associated behavior did not appear 
to be affected by mephedrone. 
 The drug seemed to produce long-term effects on 
biochemical or behavioral pathways in rodents. Marusich et 
al. [61] examined the acute effects of mephedrone, among 
other substances, on rotarod (a performance test based on a 
rotating rod with forced motor activity for evaluation of 
balance, neurotoxicity and motor coordination), locomotor 
activity and a functional observational battery. Regarding 
locomotor activity, mephedrone showed significant effects 
related to time, dose and interaction with other substances. 
Significant increases in beam breaks were produced by all 
drug doses. Dosages of 10, 3 and 30 mg/kg of mephedrone 
produced an increase in locomotor activity during the first 70 
min of the session, 20–40 min post-injection and for the 
entire session, respectively, when compared to saline. 
Results of the functional observational battery illustrated that 
mephedrone significantly increased hyperactivity, stereotyped 
head weaving and circling and stimulation. 
 A rat model study was carried out to evaluate the 
cardiovascular and behavioral effects of mephedrone. It was 
found that its discriminative stimulus effects were more 
similar to those of MDMA in comparison with those of 
methamphetamine and cocaine and not antagonized by 
haloperidol administration suggesting that the mechanism of 
action of the drug was not predominantly due to interaction 
with DA D2 receptors. Nevertheless, its actions on cardio- 
vascular activity and on acquisition behavior resemble those 
of methamphetamine [62]. 
 Recreational abusers report that a stimulant drug with 
short duration of action and rapid onset like cocaine is 
preferable, since the short duration of action allows 
successive dosing and therefore more frequent exposures to 
the desirable effects [63], suggesting that psychoactive drugs 
sharing the latter characteristics are more prone to be abused. 
Thus, synthetic cathinones such as mephedrone, MDPV and 
4-fluoromethcathinone are likely to have a non-negligible 
potential of abuse since they reveal a rapid initial increase of 
locomotor activity, which deteriorates during the session [63, 
64]. A limited set of laboratory experiments demonstrated 
that mephedrone is readily self-administered by male rats 
[34, 65-67]. The drug showed a relatively high abuse 
liability if compared to MDMA and methylone, with the 
latter drugs presenting lower and analogous liability for 
repetitive use. Ramoz et al. [68] reported that behavioral 
effects related to psychostimulant drugs such as DA- sensitive 
stereotyped movements, abstinence-induced withdrawal and 
environmental place conditioning are all produced by 
mephedrone. suggesting a strong evidence for an addiction 
liability [34, 69]. Creehan and collegues [70] were the  
first to evaluate methylone, MDMA and mephedrone self-
administration in female rats. Their findings showed that the 
intake in mephedrone-trained rodents was significantly 
higher, compared to that of methylone and MDMA-trained 
rats. Dose substitution showed that mephedrone-trained rats 
developed greater intakes of all tested compounds, suggesting 
higher abuse liability. Moreover, i.p. administration of 
mephedrone to rats at concentrations of 15 or 30 mg/kg, 
resulted in an increase in the expression of Fos protein in 
brain areas which are reward-relevant such as the ventral 
striatum, ventral tegmental and prefrontal cortex [49]. The 
fact that mephedrone owns a much faster clearance rate than 
MDMA, may rise the proclivity for repeated binge use of the 
drug [26]. 
CONCLUSION 
 Despite the increasing use of mephedrone and the 
fatalities already attributed to its intoxication [33], little 
information is still available on the mechanism of action to 
definitively establish the rate of abuse liability and 
neurotoxicity. 
 The literature regarding the neurotoxic effect of 
mephedrone in 5-HT and DA systems remains controversial. 
Although some studies on animal models have reported no 
damage to DA nerve endings in the striatum [12, 58] and no 
significant changes in brain monoamine levels [48], some 
others [34] have suggested a rapid reduction in 5-HT and DA 
transporter function following drug administration. Persistent 
serotonergic deficits were observed after binge like treatment 
in a warm environment [34] and in both serotonergic and 
dopaminergic nerve endings [58], where mice were tested for 
dose and time dependent neurotoxicity at high ambient 
temperature. Other authors [55] demonstrated oxidative 
stress cytotoxicity and an increase in lipid peroxidation in 
the frontal cortex. In vitro cytotoxic properties were also 
detected, suggesting that mephedrone may act as a reductant 
agent and can also determine changes in mitochondrial 
respiration [60]. Cytotoxic effects were also described  
by other authors and were found to be dose related [58]. 
Nevertheless, other studies have failed to show any 
persistent neurochemical effect of this drug when using long 
duration dosing protocols [47], while behavioral effects 
could still be noticed in addition to damages on the working 
memory. However, due to the differences in the design of the 
experiments, including temperature and the different species 
of rodents used, the results are difficult to compare. Moreover, 
it must be highlighted that damages were more frequently 
observed in studies carried out at high temperature (≥ 26°C) 
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mimicking the hyperthermia following the exposure to these 
mephedrone and more in general to amphetamine-like 
compounds. 
 Up to now, no clinical trials in humans, nor clinical 
observations in intoxicated users have been available to 
clearly describe pharmacology and toxicology of mephedrone 
in humans. This information is undoubtedly necessary to 
establish eventual appropriate treatments to limit mephedrone 
abuse outcomes and eventual consequences the public health. 
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